SkyePharma PLC
http://www.skyepharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SkyePharma PLC
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Carlyle Bets Big On Late-Stage Biotech With Abingworth Buy
Tapping into Abingworth’s pioneering clinical co-development model, the private equity behemoth is using that experience to form Launch Therapeutics which will seek to partner with biotech and biopharma on "best‐in‐class, late‐stage clinical assets [and] bring life‐saving therapies to market better, faster and cheaper."
Stock Watch: Brace For European Biotech Departures From NASDAQ
A NASDAQ listing has been the pinnacle for non-US biotech companies because it brings access to more specialist investors and a larger capital base. But the appetite for – and aftermarket performance of – this biotech tourism is cycle-dependent.